玛莱克琳生物技术公司Moleculin Biotech, Inc. （MBRX） 2016年10-K年度报告「NASDAQ」.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.,20549 FORM 10-K xx ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,2016Commission File Number:001-37758 Moleculin Biotech,Inc.(Exact name of registrant as specifi

2、ed in its charter)Delaware283447-4671997(State or Other Jurisdiction of(Primary Standard Industrial(I.R.S.EmployerIncorporation or Organization)Classification Code Number)Identification Number)2575 West Bellfort,Suite 333Houston,Texas 77054(713)300-5160(Address,Including Zip Code,and Telephone Numbe

3、r,Including Area Code,of Registrants Principal Executive Offices)Securities registered pursuant to Section 12(b)of the Act:Common Stock,par value$0.001per share Securities registered pursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as

4、defined in Rule 405 of the Securities Act.YES NO x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Act.YES NO x Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of t

5、he Securities ExchangeAct of 1934 during the preceding 12 months(or for such shorter periods as the registrant was required to file such reports)and(2)has beensubject to such filing requirements for the past 90 days.YES x NO Indicate by check mark whether the registrant has submitted electronically

6、and posted on its corporate Website,if any,every InteractiveData File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months(or for such shorterperiod that the registrant was required to submit and post such files).YES x NO Indicate by check mark if